ReviewJournal of artificial organs : the official journal of the Japanese Society for Artificial Organs2025
Current status and challenges of DCD heart transplantation in the Asia-Pacific region.
Review in Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart transplantation remains the definitive treatment for end-stage heart failure, but donor shortages persist globally. This review aims to evaluate the current status, enabling technologies, ethical considerations, and future prospects of donation after circulatory death (DCD) heart transplantation in the Asia-Pacific region. A comprehensive narrative review was conducted using published literature and country-specific reports to assess global and regional trends in DCD heart transplantation. Particular focus was given to enabling technologies (e.g., thoracoabdominal normothermic regional perfusion [taNRP] and ex situ machine perfusion), legal and ethical frameworks, and implementation barriers across countries in the Asia-Pacific. While countries such as the UK, US, and Australia have achieved comparable survival outcomes between DCD and donation after brain death (DBD) heart transplantation, most Asia-Pacific countries remain in early stages. Australia leads the region with over 70 successful DCD heart transplants using the Organ Care System. Japan lacks legal clarity and clinical protocols for withdrawal of life-sustaining therapy, restricting DCD to kidney transplants. China employs a hybrid DBCD model but faces logistical and ethical constraints. In South Korea, India, and others, DCD heart programs are not yet established. High cost and limited availability of enabling technologies, alongside ethical controversy surrounding taNRP, are key barriers. Broader adoption of DCD heart transplantation in Asia-Pacific countries requires legal reform, ethical consensus, cost-effective perfusion strategies, and public engagement. Coordinated efforts across technological, societal, and regulatory domains are essential to expand access to this life-saving modality.
Indexed as
Identifiers
40423750What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.